Kornimate/medical-research-clean huggingface dataset:
early childhood caries and health professionals' perception: a qualitative research protocol to assess oral health stigma

Conditions: Early Childhood Caries (ECC)

Summary: dental caries is the most common non-communicable disease in childhood. disease management of caries rests on surgical treatment as well as various preventive strategies such as fluoridation, sealants, personal counselling... with other non-communicable diseases (obesity, overweight...), it has been demonstrated that health professionals' negative perceptions of their patients could affect disease management quality. concerning dental caries, some data might suggest that discriminating believes and behaviours toward children with dental caries and their families exist in the medical setting. however, oral health related stigma remains an unexplored issue. this study would be the first to our knowledge to specifically address the question of stigmatisation and discrimination of patients with dental caries. the present project is to conduct an exploratory study focusing on perceptions and attitudes of health professionals toward children with early childhood caries and their parents. the questions the study aims to answer are: (i) what are health professionals 'perceptions of children with ecc and their family? and (ii) according to health professionals, do these perceptions influence the quality of their care? we hypothesize that some practitioners have negative opinions on children with ecc and their parents, affecting the quality of their care, especially concerning oral health prevention. method: individual semi-structured interviews will be conducted among dentists (general or pediatric), general practitioners and paediatricians.


Eligibility criteria:
inclusion criteria: * speak french fluently * practice with children as a dentist (general or pediatric), a general practitioner, or a paediatrician * work in hospital or ambulatory facility exclusion criteria: * na

Keywords: dental caries social stigma child qualitative study
observation of emergency obstetrical situations.

Conditions: Unspecified Obstetrical Trauma, With Delivery; Emergencies

Summary: the teamobs study is an observational study. we analyze actually recordings of obstetric emergencies to get an even better understanding and knowledge of the association between the communication and cooperation and the quality of the performance of the interdisciplinary team.

background: in obstetric emergency situations (oes) inadequate non-technical skills (nts) are the leading causes of substandard care. aim: based on live audio and video (av)-recordings of real (oes) the aim is to describes how the nts and the clinical performance are related. method: 1. inclusion of the teams. oes teams from the delivery ward at two danish hospitals, aarhus university hospital and horsens regional hospital are av-recorded are collected and saved for analyzing with consent from all participant. 2. develop a scoring tool to rate clinical performance in oes. 12 ekspert senior obstetricians from different maternity units in britain, norway, sweden, denmark and iceland volunteered to join the delphi panel and develop a clinical performance tool. 3. rate clinical performance. using the developed tool in 2) to rate live teams 4. rate nts recording of teams will be rated by the validated list: assessment of obstetric team performance with the validated tool from pamela morgan: aotp. furthermore important observations will be code. video assessments is planned for 2016-2018 5. explore the association between clinical performance and nts in oes. results from 3) and 4) will be compared. discussion: we expect that this study will add to the knowledge of nts and the effect on clinical performance in oes.

Eligibility criteria:
inclusion criteria: video recordings of emergency situations in simulation aswell live will include management of every day situations as well as rare emergencies, with the inclusion criteria of obstetric teamwork: \>2 healthcare personal present and one of them an obstetrician. the five situations in are study are the following: 1. eclampsia, 2. post-partum haemorrhage, 3. new -born resuscitation (apgar ≤ 7/5 min), 4. shoulder dystocia and 5. instrumental delivery. the situation can be included if a video recording is capture of the event and all participant in the video have given informed consent. exclusion criteria: absent informed consent.
endolaparoscopic versus immediate surgery for obstructing colorectal cancers

Conditions: Colorectal Cancer; Bowel Obstruction

Summary: the aim of this study is to compare the stoma rate, clinical efficacy, and safety of patients treated by endoscopic stenting followed by elective laparoscopic resection (the 'endolaparoscopic approach') versus immediate emergency surgery for obstructing left-sided colorectal cancers.

in patients who present with obstructing left-sided colorectal cancers, emergency surgery carries a significant morbidity and mortality. traditionally, most of these patients would receive staged operations (hartmann's procedure). temporary stoma is often required due to the edematous bowel wall precluding primary anastomosis as a result of obstruction and the poor pre-morbid status. a second operation is subsequently required to restore bowel continuity. apart from the expensive hospital costs of the staged operations, the patient's acceptance to the stoma is poor and the social inconvenience associated with the stoma is obvious. thus, a significant portion of patients would not be suitable for the second operation due to poor health or advanced disease and having to bear the stoma for the remainder of life. recently, self-expandable metal stents have been used with success in relieving the acute obstruction in patients with obstructing left-sided colorectal cancers. endoscopic stenting may help to relieve the obstruction, avoid emergency surgery, and allows patients to undergo one-stage elective surgery without the necessity of making a stoma. we propose to evaluate the clinical benefits of using self-expandable metal stents in patients with obstructing left-sided colorectal cancers followed by elective laparoscopic resection and compare its use to immediate emergency surgery.

Eligibility criteria:
inclusion criteria: * consecutive patients with obstructing colorectal cancers, confirmed on water-soluble contrast enema or computed tomography (ct) scan * consented patients exclusion criteria: * patients with peritonitis that required immediate surgical intervention * patients with distal rectal cancers that are not suitable for stenting * moribund patients, unfit for surgery otherwise * pregnancy

Keywords: obstructing left-sided colorectal neoplasms obstructing left-sided colorectal cancers
laser and radiofrequency and genitourinary syndrome of menopause

Conditions: Postmenopausal Atrophic Vaginitis; Postmenopausal Symptoms; Genitourinary Symptoms

Summary: this is a randomized controlled trial to evaluate the use of laser, micro ablative radiofrequency and topic strogen to treat symptoms of vulvovaginal atrophy of post menopause.

post menopause women with moderate or severe signs or symptoms of vulvovaginal atrophy will be eligible for the study. the patients will be randomized to receive one of the three intravaginal therapies: laser, micro ablative radiofrequency or estriol. the applications will occur in the interval of 30 days for 3 times, for laser and radiofrequency groups. for the estriol group, the application will be done by the patient, daily for 2 weeks and them twice a week for 3 months, and each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube, to verify the correct use. the follow-up visits will occur 30, 90, 180 and 360 days after the conclusion of the third month of treatment. will be evaluated: vulvar and vaginal histology before and after the use of laser, radiofrequency or estriol; microbiota and vaginal ph before and after the use of laser, radiofrequency or estriol; extracellular matrix and metalloproteinases in the remodeling of vulvovaginal collagen induced by estrogen, laser and radiofrequency; quality of life, sexual dysfunctions and complaints before and after the use of laser, radiofrequency or hormones; metabolomics and vaginal microbiome.

Eligibility criteria:
inclusion criteria: 1. women between 2 and 5 years after menopause, without hormone therapy for at least 2 years 2. to present, at least moderate, or severe intensity (score 4 or more of visual analog scale ( 0-10)) of one of the signs or symptoms of of vulvovaginal atrophy: * burning * discomfort * dryness * cracks * pruritus * lack of vaginal lubrication * penetration dyspareunia that began at the menopausal or postmenopausal transition * decreased vaginal epithelium turgor and trophism * deletion of mucous and skin folds. the exclusion criteria will be: 1. active genital infection, active infection of hpv (human papillomavirus) or herpes, users of medications with estrogenic effect (digoxin, tamoxifen and other chemicals) 2. postmenopausal genital bleeding, uncontrolled diabetes, use of multivitamins with zinc, use of copper or hormonal iuds (intrauterine device) at the time of inclusion, presence of genitourinary or rectovaginal fistulas.

Keywords: postmenopause atrophic vaginitis vulvovaginal atrophy treatment laser radiofrequency estriol strogen therapy
muscle vibration as a countermeasure against hypoactivity-induced

Conditions: Vibration Therapy; Healthy Volunteer Study; Hypoactivity

Summary: muscle deconditioning, characterized by a loss of muscle mass and strength, is a frequent consequence of prolonged lower limb unloading. beyond muscle mass loss, reduced neural drive contributes significantly to strength decline, highlighting the need for interventions targeting neuromuscular function during immobilization. focal muscle vibration (fmv) has shown promise in modulating neuromuscular excitability by activating muscle spindle afferents and inducing cortical adaptations. chronic use of fmv has been associated with significant strength gains and improved neural command. this makes fmv an effective rehabilitation tool. its simplicity and non-invasiveness further make it a practical countermeasure.

this study hypothesizes that a 10-day fmv protocol can induce neural adaptations to limit strength loss during unilateral lower limb suspension, offering a novel strategy against neuromuscular function decline.

Eligibility criteria:
inclusion criteria: * men and women. * aged 18 to 45 years. * body mass index (bmi) between 20 and 25 kg/m². * engaging in at least 1.5 hours per week of physical activity (e.g., brisk walking, running, swimming, cycling). * provided informed consent after receiving detailed information about the study. * affiliated with or beneficiaries of a social security system exclusion criteria: * chronic cardiovascular, neuromuscular, bone, metabolic, and/or inflammatory disorders. * personal history and/or risk factors for thrombosis. * use of antidepressant medications. * use of neuroactive substances likely to alter corticospinal excitability (e.g., hypnotics, antiepileptics, psychotropics, muscle relaxants) during the study. * recent bone or ligament trauma within the past 12 months. * inability to perform the physical efforts required for the study. * recent participation in a sporting competition or intense, unusual physical activity within the past month. * corticosteroid treatment within the past 3 months. * any skin lesions at the planned vibrator application site. * simultaneous participation in another interventional medical study. * pregnant or breastfeeding women. * individuals unable to understand the purpose and conditions of the study or unable to provide informed consent. * individuals deprived of liberty or under guardianship

Keywords: hypoactivity neuromuscular deconditionning vibration
shr-1701 in subjects with metastatic or locally advanced solid tumors

Conditions: Solid Tumor

Summary: the main purpose of this study is to assess the safety and tolerability of shr-1701 at different dose levels. study consists of dose-escalation part and an expansion part in subjects with metastatic or locally advanced solid tumors.

this is a phase i, open-label, multiple-ascending dose trial. study consists of dose-escalation part in subjects with metastatic or locally advanced solid tumors, and expansion part with selected indications.

Eligibility criteria:
inclusion criteria: * able and willing to provide signed informed consent form, and able to comply with all procedures. * histologically or cytologically proven metastatic or locally advanced solid tumors. * male or female subjects aged 18-75 years. * life expectancy \>= 12 weeks as judged by the investigator. * eastern cooperative oncology group (ecog) performance status of 0 to 1 at trial entry. * disease must be measurable with at least 1 uni dimensional measurable lesion by response evaluation criteria in solid tumors (recist) version 1.1. * adequate hematological, hepatic and renal function as defined in the protocol other protocol-defined inclusion criteria could apply. exclusion criteria: * prior therapy with an anti-pd1, anti-pd-l1, anti-ctla-4 or a tgfb inhibitor. * anticancer treatment within 28 days before the first dose of study drug. * major surgery within 28 days before start of trial treatment. * systemic therapy with immunosuppressive agents within 7 days prior to the first dose of study drug; or use any investigational drug within 28 days before the start of trial treatment. * with any active autoimmune disease or history of autoimmune disease. * with active central nervous system (cns) metastases causing clinical symptoms or requiring therapeutic intervention. * clinically significant cardiovascular and cerebrovascular diseases * history of immunodeficiency including seropositive for human immunodeficiency virus (hiv), or other acquired or congenital immunedeficient disease, or any active systemic viral infection requiring therapy. * previous malignant disease (other than the target malignancy to be investigated in the trial) within the last 2 years. subjects with history of cervical carcinoma in situ, superficial or non-invasive bladder cancer or basal cell or squamous cell cancer in situ previously treated with curative intent are not excluded. * receipt of any organ transplantation, including allogeneic stem-cell transplantation other protocol-defined exclusion criteria could apply

Keywords: shr-1701 solid tumor metastatic or locally advanced solid tumors
telerehabilitation in covid-19 survivors

Conditions: COVID-19; Telerehabilitation

Summary: this study was carried out in the post-acute period of the telerehabilitation program in individuals with dyspnea who had covid-19; it will be done to examine the effects on dyspnea, exercise capacity, respiratory functions, activities of daily living, muscle strength, muscle oxygenation, fatigue and quality of life parameters.


Eligibility criteria:
inclusion criteria: * diagnosed with covid-19 by computed tomography (ct) or pcr test between the ages of 18-75, * do not have any orthopedic or neurological disease that will affect exercise capacity, * individuals who can take and execute verbal orders, * have had covid-19 and at least 2 weeks have passed since the completion of the treatment, * individuals who have a computer or smart phone with a camera and internet connection and have the ability to use it (the participant himself or one of his family members living in the same house), * individuals who are sedentary (those whose physical activity level is inactive according to the turkish version of the international physical activity questionnaire (ufaa)), * having dyspnea at level 2 or 3 on the medical research council dyspnea scale. exclusion criteria: * those who have not had covid-19 or acute period patients who are experiencing covid-19, * individuals who cannot be contacted, * individuals with chronic heart disease, * those with concomitant uncontrolled disease; uncontrolled hypertension (resting blood pressure ≥160 /100mmhg), uncontrolled diabetes (random instantaneous blood glucose\>16.7 mmol/l, hba1c\>7.0%), * those with concomitant severe organic disease (unstable hemodynamic heart disease, heart failure causing movement limitation, unstable angina, mi or other cardiac disease in the last 12 years), * individuals with cerebrovascular disease in the last 6 months, * those with digestive system ulcer, thyroid dysfunction or active stage of tuberculosis, * patients with chronic kidney failure stage 3 and above according to glomerular filtration rate (gfr), * individuals who have undergone intraraticular medication or surgery from their lower extremities in the last 6 months, * individuals who cannot walk independently, * individuals with any mental illness that may prevent them from living independently or receiving treatment, * uncooperative individuals for assessment and rehabilitation programs, * those with alcohol or substance addiction, * those who are pregnant, suspected of pregnancy or considering becoming pregnant, * participants in another study within the last 3 months or currently.

Keywords: covid-19 telerehabilitation covid-19 survivors functional capacity pulmonary functions peripheral muscle oxygenation home workout program
intelligent follow-up of neonatal jaundice based on early indicators and internet communications

Conditions: Hyperbilirubinemia, Neonatal

Summary: in this prospective multi-center randomized clinical trial, a new follow-up strategy for neonatal jaundice after discharge will be evaluated. it is based on current risk factors of neonatal hyperbilirubinemia, added with the rate of bilirubin production (exhaled carbon monoxide measurement) as a new indicator,and incorporated with internet plus technology. traditional methods following the chinese guideline for neonatal hyperbilirubinemia were applied in the control group. the morbidity of bind, the number of outpatient follow-up after discharge and the convenience will be compared between the two groups. the accuracy, effectiveness, safety and convenience of the study strategy will be testified.

the eligible newborns will be randomized into two groups: the study group (innovative strategy) and the controlled group (traditional strategy). the innovative strategy included the etcoc measurement in the risk evaluating process and the internet plus approach in the follow-up process.

Eligibility criteria:
inclusion criteria: 1. gestational age between 35(+0)\~41(+6) 2. birth weight ≥ 2500 g 3. ethics approval obtained 4. parental consent obtained exclusion criteria: 1. severe perinatal asphyxia 2. infectious diseases 3. persistent need for respiratory support 4. major congenital malformation 5. inborn errors of metabolism 6. pathological neonatal hyperbilirubinemia due to the defects of red blood cell membrane and erythrocyte enzyme

Keywords: end tidal carbon monoxide internet plus jaundice follow-up management model
suprachoroidal administration in subjects with choroidal metastasis from breast or lung primary tumors

Conditions: Eye Cancer; Metastatic Breast Cancer; Lung Cancer

Summary: the primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with choroidal metastasis from breast or lung primary tumors.

this is an open-label, dose escalation trial designed to assess safety and tolerability of 4 dose strengths and 1-2 cycles of bel-sar treatment in subjects with choroidal metastasis from breast or lung primary tumors.

Eligibility criteria:
inclusion criteria: * have a clinical diagnosis of choroidal metastasis, from a histopathologically or cytologically confirmed breast or lung primary tumor. * have a single choroidal metastasis in only 1 eye, and no choroidal metastasis in the other eye (i.e., unilateral, unifocal choroidal metastasis). exclusion criteria: * active ocular infection or disease. * must not have evidence of a primary tumor or metastatic lesion in the brain requiring treatment with radiation therapy per the primary treating oncologist's assessment.

Keywords: choriodal metastatis metastasis to the choroid ocular eye
ak112 neoadjuvant/adjuvant treatment for resectable nsclc

Conditions: Resectable Non-small Cell Lung Cancer

Summary: ak112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable nsclc

phase ii clinical study of ak112, an anti-pd-1 and vegf bispecific antibody, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable non-small cell lung cancer

Eligibility criteria:
inclusion criteria: 1、18 to 75 years old 2、be able and willing to provide written informed consent and to comply with all requirements of study participation 3、histologically confirmed resectable stage ii-iiib nsclc 4、have an eastern cooperative oncology group (ecog) performance status of 0 or 1 5、has adequate organ function 6、all female and male subjects of reproductive potential must agree to use an effective method of contraception, as determined by the investigator, during and for 120 days after the last dose of study treatment. exclusion criteria: 1. is currently participating in a study of an investigational agent or using an investigational device 2. has an active autoimmune disease that has required systemic treatment in the past 2 years 3. has an active infection requiring systemic therapy 4. has known active hepatitis b (e.g., hbsag reactive) or hepatitis c (e.g., hcv rna \[qualitative\] is detected) 5. has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study 6. has received a live virus vaccine within 30 days prior to first dose of study treatment 7. is pregnant, breastfeeding, or expecting to conceive or father a child within the projected duration of the study including 120 days following the last dose of study treatment.
using technology to address disparities and promote healthcare equity in type 1 diabetes registry

Conditions: Diabetes Mellitus, Type 1

Summary: this study is being done to see if using technology, with the help of a patient navigator, can help address disparities, improve outcomes, and promote healthcare equity in type 1 diabetes.

patients with t1d require an individualized care plan with ongoing education and support. a recent qualitative study of young adults with t1d and end-stage renal disease revealed that childhood environment, education, socio-economic status, and other determinants contributed to disengagement from treatment regimens and the development of microvascular complications early in life1. providing participants with real-time cgms will inform daily decision making. this is an interventional study using prescribed real-time cgms together with feedback and support from a patient navigator in patients with t1d. the aims of this study include the following. aim 1: to incorporate real-time cgms and patient navigation support into the care of adolescent and adult patients with t1d and one of the following: 1.) two or more hospitalizations for dka in the last five years or 2.) two or more hemoglobin a1c values over 10% in the last two years. aim 2: to collect information from participants regarding health outcomes, experiences with health care, and changes, if any, in diabetes self-management practices, diabetes distress, and diabetes health-related quality of life.

Eligibility criteria:
inclusion criteria: * males or females age 14 to 64 years * clinical diagnosis of type 1 diabetes (t1d) * two or more hospitalizations with diabetic ketoacidosis (dka) within the past 5 years or hemoglobin a1c greater than 10% on two or more laboratory samples in the last 2 years. * informed consent * has a cgms or a prescription for a cgms as part of their clinical care as part of their clinical care exclusion criteria: * inability or unwillingness to share cgms data with the study team